Carcinoma, Hepatocellular: all 3,249 studies
Page 8 of 33. Open to participants first (974), then studies with results posted, then the rest; newest registration first within each.
- Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular CarcinomaRecruitingNCT05970666Phase 2
- Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With SurgeryRecruitingNCT05970159
- Predictors of Sorafenib Response in HCCNot yet recruitingNCT05967429
- Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)RecruitingNCT05967143
- Pulmonary Function Tests Study in Cirrhotic Patients With and Without Hepatocellular CarcinomaNot yet recruitingNCT05963776
- Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor TherapyRecruitingNCT05962450Phase 2
- Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT05957640Phase 1
- Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular CarcinomaRecruitingNCT05954897Phase 2
- 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With HypoalbuminemiaRecruitingNCT05953961Not applicable
- FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint InhibitionRecruitingNCT05937295Phase 1
- Establishment of a Tissue Registry for Hepatocellular Carcinoma SpecimensRecruitingNCT05935189
- Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of IndicatorsRecruitingNCT05932719
- GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular CarcinomaRecruitingNCT05926726Not applicable
- Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05924997Phase 1/2
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
- FOG-001 in Locally Advanced or Metastatic Solid TumorsRecruitingNCT05919264Phase 1/2
- Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCCRecruitingNCT05917431Phase 2
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingNCT05914116Phase 1/2
- Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or AblationNot yet recruitingNCT05910970Phase 3
- Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular CarcinomaNot yet recruitingNCT05908916Phase 2
- Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05903456Phase 2
- A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaRecruitingNCT05901519Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
- A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker AnalysesNot yet recruitingNCT05897138Phase 2
- Goal-directed LCVP Based on HP in Laparoscopic HepatectomyRecruitingNCT05887661Not applicable
- Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving HepatectomyNot yet recruitingNCT05887505Not applicable
- HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialRecruitingNCT05886465Phase 2
- TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven CriteriaNot yet recruitingNCT05883176Phase 2
- TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II StudyRecruitingNCT05882370Phase 2
- The ImmunoXXL StudyRecruitingNCT05879328
- M-TACE Treatment for Unresectable Hepatocellular CarcinomaEnrolling by invitationNCT05875558Not applicable
- H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein ThrombosisNot yet recruitingNCT05872841Phase 2
- 18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular CarcinomaRecruitingNCT05871892Not applicable
- Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)RecruitingNCT05870969
- Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular CarcinomaRecruitingNCT05866783
- HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCCRecruitingNCT05866172Phase 3
- HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular CarcinomaRecruitingNCT05864755Phase 2
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Phase 3
- Navigating the Clinical Trial Process for Hepatocellular CarcinomaNot yet recruitingNCT05859945
- Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
- Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT05844046Phase 2
- Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCRecruitingNCT05842317Phase 1/2
- Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular CarcinomaRecruitingNCT05842174Phase 1/2
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCCRecruitingNCT05839197Phase 2
- Improving Hepatocellular Carcinoma ScreeningRecruitingNCT05828446Not applicable
- HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT05821361Phase 2
- Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted TherapyRecruitingNCT05811481
- Liver Cancer and Immunotherapy in the Liquid Biopsy EraRecruitingNCT05810402Not applicable
- Immunotherapy and Radioembolisation for Metastatic Hepatocellular CarcinomaRecruitingNCT05809869Phase 2
- Ablation in Combination With Lenvatinib and Anti-PD-1 AntibodiesRecruitingNCT05803928Phase 1
- METabolic PROFILE of Hepatocarcinoma and Pancreatic TumorsRecruitingNCT05794048Not applicable
- To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307RecruitingNCT05783570Phase 1
- Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)RecruitingNCT05781568
- Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesRecruitingNCT05771025Not applicable
- The Application of Serum DNA Methylation for Patients With HCCRecruitingNCT05764551Not applicable
- Ate-Bev Early Response Prediction Model in Advanced HCCRecruitingNCT05763277
- Clinical Study of mRNA Vaccine in Patients With Liver Cancer After OperationNot yet recruitingNCT05761717Not applicable
- Identification and Prognostic Value of Key Genes in Hepatocellular CarcinomaRecruitingNCT05759858
- A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular CarcinomaNot yet recruitingNCT05752890
- Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialRecruitingNCT05751343Phase 2
- Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3RecruitingNCT05738980Not applicable
- Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)RecruitingNCT05738616Phase 3
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCRecruitingNCT05733598Phase 2
- Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCCRecruitingNCT05729867Not applicable
- A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic AgentsRecruitingNCT05718492Not applicable
- SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)Not yet recruitingNCT05718232Phase 3
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT05717738
- Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT05713994
- Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCCNot yet recruitingNCT05711823Phase 3
- Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for PatientsRecruitingNCT05705219
- CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)RecruitingNCT05704192
- Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)RecruitingNCT05703750
- Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular CarcinomaRecruitingNCT05701553
- Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)RecruitingNCT05690048Phase 2
- Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular CarcinomaRecruitingNCT05687747Phase 1
- Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor BoardsNot yet recruitingNCT05681949Not applicable
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05675462Phase 1
- AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular CarcinomaRecruitingNCT05669339Phase 2
- A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver CancerNot yet recruitingNCT05660213
- Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCCRecruitingNCT05652920Phase 1/2
- Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma PatientsRecruitingNCT05629845Not applicable
- Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal ImageRecruitingNCT05627297
- Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular CarcinomaRecruitingNCT05626985
- CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic SyndromeRecruitingNCT05623150
- Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskRecruitingNCT05620771Phase 2
- Study of GPC-3 CAR-T Cells in Treating With Hepatocellular CarcinomaRecruitingNCT05620706Not applicable
- Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingNCT05613478Phase 3
- Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05609695
- MRI-guided Holmium-166 RadioembolizationEnrolling by invitationNCT05609448Not applicable
- Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCCRecruitingNCT05608213Phase 3
- Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCCRecruitingNCT05608200Phase 3
- Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III StudyNot yet recruitingNCT05602974Not applicable
- Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCCRecruitingNCT05596630Not applicable
- Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)RecruitingNCT05594927Phase 3
- Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular CarcinomaNot yet recruitingNCT05582109Phase 2
- Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular CarcinomaRecruitingNCT05573282
- Lenvatinib Therapy in HCC Patients After LDLTRecruitingNCT05572528
- Prospective Cohort for Early Detection of Liver CancerRecruitingNCT05541601
- The Detection of Small Early Liver Cancer With Natural History Follow upRecruitingNCT05534906